Anxiety Disorders

FDA signals clear IND path for PT00114, a first-in-class neuropeptide aiming to reset stress responses in patients with generalized anxiety disorder.

DT120 (lysergide) hits all endpoints in phase 3 GAD trial, cutting anxiety scores with a single dose.

Learn how clinicians tailor simple, measurable activity plans that boost depression and anxiety treatment—and improve long‑term adherence.

Concussion recovery in teen athletes often masks anxiety or depression; learn warning signs, screening tips, and safer return-to-play steps.

Phase 3b trial shows centanafadine eases adult ADHD and anxiety symptoms fast, with expected safety profile, as FDA review nears.

Synendos launches a phase 2 trial of SYT-510, a first-in-class endocannabinoid modulator, aiming to ease generalized anxiety symptoms with improved safety and adherence.

Lifestyle medicine pillars help reshape depression and anxiety treatment in psychiatry.

Learn how antipsychotics and stress raise prolactin, what symptoms to spot, and when to test—plus practical options to lower levels.

Two-dose oral R‑MDMA, EMP-01, cuts social anxiety symptoms and real‑world avoidance in phase 2a study, with strong responder rates and good tolerability.

A pharma expert and clinician shares perspectives on developing treatments.

A new US Department of War backed phase 2a study will test BXCL501's efficacy in easing acute stress reactions and preventing PTSD.

A novel form of agomelatine shows positive initial results.

An interview with Felice Jacka, OAM, PhD, on the rapidly developing field of nutritional psychiatry.

New phase 2 data show HLP004 boosts standard antidepressants for moderate-to-severe GAD.

New research highlights psilocybin's potential in treating treatment-resistant OCD, while cannabinoids show little evidence of efficacy.

Preclinical mGlu7 negative allosteric modulator ADX71743 disrupts fear-memory reconsolidation.

Athletes navigate stress as a performance factor, learning to harness it for optimal results through effective management strategies and support systems.

Vistagen's fasedienol fails to show significant efficacy in treating social anxiety disorder, despite favorable safety data from the PALISADE-3 trial.

Incannex Healthcare's PSX-001 shows promise in treating generalized anxiety disorder, offering innovative, effective solutions beyond traditional therapies.

Explore how placebo effects vary across psychiatric disorders, revealing significant symptom improvements, especially in major depressive disorder and generalized anxiety disorder.

Semaglutide shows promise in enhancing cognitive function for individuals with psychiatric disorders, particularly improving memory and overall cognitive outcomes.

Synendos Therapeutics reveals promising phase 1 results for SYT-510, a novel ECS modulator targeting anxiety and CNS disorders with potential for improved patient outcomes.

New study shows lumateperone (Caplyta) significantly improves symptoms in major depressive disorder with anxious distress, offering hope for treatment-resistant patients.

New research reveals ART12.11, a cannabidiol:tetramethylpyrazine cocrystal, significantly enhances mood regulation, outperforming traditional cannabidiol in treating mood and anxiety disorders.

Neuphoria Therapeutics announces successful enrollment in a pivotal trial for BNC-210, a promising treatment for social anxiety disorder.